263 related articles for article (PubMed ID: 37211261)
1. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
Stewart AG; Bauer MJ; Butkiewicz D; Hinton A; Henderson A; Harris PNA; Paterson DL
Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
[TBL] [Abstract][Full Text] [Related]
2.
Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
[TBL] [Abstract][Full Text] [Related]
3. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
[No Abstract] [Full Text] [Related]
4.
Gupta A; Malik S; Kaminski M; Landman D; Quale JM
Microb Drug Resist; 2022 Apr; 28(4):419-424. PubMed ID: 35451880
[TBL] [Abstract][Full Text] [Related]
5. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
Birgy A; Madhi F; Jung C; Levy C; Cointe A; Bidet P; Hobson CA; Bechet S; Sobral E; Vuthien H; Ferroni A; Aberrane S; Cuzon G; Beraud L; Gajdos V; Launay E; Pinquier D; Haas H; Desmarest M; Dommergues MA; Cohen R; Bonacorsi S;
J Antimicrob Chemother; 2021 Oct; 76(11):2839-2846. PubMed ID: 34453533
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genes.
Mendes RE; Rhomberg PR; Watters AA; Castanheira M
J Antimicrob Chemother; 2022 Feb; 77(3):689-694. PubMed ID: 34849977
[TBL] [Abstract][Full Text] [Related]
7. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Bauernfeind A; Jungwirth R
Infection; 1991; 19(5):353-62. PubMed ID: 1800377
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
Rawat D; Hasan AS; Capoor MR; Sarma S; Nair D; Deb M; Pillai P; Aggarwal P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):131-9. PubMed ID: 19323045
[TBL] [Abstract][Full Text] [Related]
12. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers.
Livermore DM; Hope R; Mushtaq S; Warner M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():189-93. PubMed ID: 18154546
[TBL] [Abstract][Full Text] [Related]
13. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of
Karlowsky JA; Wise MG; Hackel MA; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0093422. PubMed ID: 36286518
[TBL] [Abstract][Full Text] [Related]
14. Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.
Stewart AG; Harris PNA; Henderson A; Schembri MA; Paterson DL
J Antimicrob Chemother; 2020 Sep; 75(9):2384-2393. PubMed ID: 32443141
[TBL] [Abstract][Full Text] [Related]
15. Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula.
Medeiros AA; Crellin J
Pediatr Infect Dis J; 1997 Mar; 16(3 Suppl):S49-55. PubMed ID: 9076836
[TBL] [Abstract][Full Text] [Related]
16.
Karlowsky JA; Hackel MA; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134622. PubMed ID: 36602322
[TBL] [Abstract][Full Text] [Related]
17. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
Al-Tamimi M; Albalawi H; Shalabi M; Abu-Raideh J; Khasawneh AI; Alhaj F
Ann Clin Microbiol Antimicrob; 2022 May; 21(1):20. PubMed ID: 35599329
[TBL] [Abstract][Full Text] [Related]
18. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
Moland ES; Sanders CC; Thomson KS
J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
[TBL] [Abstract][Full Text] [Related]
19. Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of
Chatwin CL; Hamrick JC; Trout REL; Myers CL; Cusick SM; Weiss WJ; Pulse ME; Xerri L; Burns CJ; Moeck G; Daigle DM; John K; Uehara T; Pevear DC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0055221. PubMed ID: 34001510
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the effectiveness of three different cephalosporin/clavulanate combinations for the phenotypic confirmation of extended-spectrum beta-lactamase producing bacteria isolated from urine samples at National Public Health Laboratory, Kathmandu, Nepal.
Bhandari R; Pant ND; Poudel A; Sharma M
BMC Res Notes; 2016 Aug; 9():390. PubMed ID: 27488224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
